Joshua Fitch, Senior Editor

The 5-in-1 vaccine candidate has the potential to reduce shots and simplify the immunization process.

“These findings suggest that primordial and primary interventions to prevent and reduce elevated childhood non–HDL-C levels may help prevent premature CVD," wrote the study authors.

The low-dose, coformulated regimen was well tolerated, and overall data supports its use in children with HIV aged 2 years and older weighing between 30.86 lbs (14 kg) and 55.11 lbs (25 kg).

The monoclonal antibody was approved by the FDA on July 17, 2023 and quickly saw high demand at the onset of the RSV season.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Allison Scott, DNP, CPNP-PC, IBCLC, reviews the updated breastfeeding guidelines from the American Academy of Pediatrics.

Juanita Mora, MD, breaks down the FDA approval of benralizumab as an add-on maintenance therapy among patients with severe asthma aged 6 to 11 years.

April 10, 2024 is National Youth HIV & AIDS Awareness Day.

When deciding whether to keep their child home from school, 4% of parents contacted a health care provider for advice.

"Our findings provide evidence for a direct association between maternal smoking during pregnancy and wheeze occurrence," wrote the authors.

The treatment is approved for adolescents aged 12 years and older.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Natasha Hoyte, MPH, CPNP-PC, explains how important PrEP and PEP in school health programs can be for youth, and the crucial role awareness plays.

Lauren Flagg, DNP, APRN, CPNP-AC, discusses severe refractory status asthmaticus based on a session presented at the NAPNAP National Conference.

Of the 600,238 bivalent vaccine doses administered by all providers in the study period, 35,114 (5.9%) were done so by FRPP partners.

The pediatric approval to treat CABP is 1 of 3 indications approved by the FDA.

The single-arm study has an estimated enrollment of 93 participants, made up of females aged 2 to 8 years and males aged 2 to 9 years with CPP.

The phase 3 portion of the AMPLITUDE trial will include adolescents aged 10 to 17 years.

The planned phase 1/2 INSPIRE Duchenne trial (NCT06138639) is a first in-human, open-label, multicenter trial to evaluate tolerability and safety of SGT-003.

Chris Kyper, DNP, CPNP-AC/PC, breaks down characteristics of Heparin-induced thrombocytopenia, an uncommon adverse reaction to heparin.

A discussion of human trafficking awareness and what primary care providers can do to spot red flags and implement evidence-based knowledge.

Get caught up with our journal! Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

If approved, govorestat would be the first medication indicated for the treatment of galactosemia, a rare genetic metabolic disease resulting in an inability to metabolize simple sugar galactose.

Tenofovir alafenamide was approved in 2022 to treat pediatric patients aged 12 years and older.

Insights between the pandemics, with a highlight on the dose-response relationship, "could be valuable in preparing health care systems for future pandemics," concluded the investigators.

Sally Humphrey, DNP, APRN, CPNP-PC, discusses current technology to treat youth with diabetes. Humphrey highlights continuous glucose monitoring systems (CGMs) and how they have evolved and improved.

Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, provided a review and reminder of the CDC immunization recommendations and schedule during her session at the 45th National Association of Pediatric Nurse Practitioners (NAPNAP) National Conference on Pediatric Health Care in Denver, Colorado.

Ashley Gyura, DNP, CPNP-PC, provides updates presented at the 2024 NAPNAP National Conference, highlighting antiviral therapeutics for influenza, COVID-19, and herpes, among others.

TNX-2900 was previously granted Orphan Drug designation by the federal agency in 2022 for the treatment of PWS.

The initial dose of pemivibart is 4500 mg, which is administered as a single intravenous infusion. A repeat 4500 mg dose should be administered every 3 months if ongoing protection is needed, stated the FDA.